Sign In
30 Jun 2025 14:15
30 June 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of AGM
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.
Resolution | For | For% | Against | Against% | Total | Witheld votes* |
Ordinary Resolution 1 To receive the annual report and audited accounts for the year ended 31 December 2024 | 30,108,642 | 99.98% | 7,304 | 0.02% | 30,115,946 | 300,591 |
Ordinary Resolution 2 To re-elect Luke Cairns as a Director of the Company | 30,061,328 | 99.98% | 7,304 | 0.02% | 30,068,632 | 98,809 |
Ordinary Resolution 3 To re-elect Chris Britten as a Director of the Company | 30,061,328 | 99.98% | 7,304 | 0.02% | 30,068,632 | 98,809 |
Ordinary Resolution 4 To elect Michael Palfreyman as a Director of the Company | 30,085,134 | 99.97% | 8,504 | 0.03% | 30,093,638 | 80,791 |
Ordinary Resolution 5 To elect Alastair Smith as a Director of the Company | 30,078,746 | 99.97% | 8,504 | 0.03% | 30,087,250 | 80,791 |
Ordinary Resolution 6 To appoint Gravita Audit II Limited as the Companyʼs auditor and to authorise the Directors to determine their remuneration | 30,085,034 | 99.98% | 7,304 | 0.02% | 30,092,338 | 93,799 |
Ordinary Resolution 7 To authorise the Directors to allot shares |
30,060,137 |
99.98% |
7,304 |
0.02% |
30,067,441 |
92,193 |
Special Resolution 8 To disapply pre-emption rights | 29,942,019 | 99.97% | 10,004 | 0.03% | 29,952,023 | 92,393 |
*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
- Ends -
For more information please contact:
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
|
Via N4 Pharma Investor Hub: investors.n4pharma.com
https://investors.n4pharma.com/link/5PmqMP |
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44 (0)20 3657 0050 |
Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)113 730 3896
|
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.
Follow the stocks
